Cited 13 times in
Prognostic factors in small cell lung cancer: a new prognostic index in Korean patients
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김세규 | - |
dc.contributor.author | 김주항 | - |
dc.contributor.author | 박경수 | - |
dc.contributor.author | 이수현 | - |
dc.contributor.author | 정민규 | - |
dc.contributor.author | 조병철 | - |
dc.contributor.author | 최혜진 | - |
dc.contributor.author | 홍수정 | - |
dc.date.accessioned | 2015-04-23T17:47:33Z | - |
dc.date.available | 2015-04-23T17:47:33Z | - |
dc.date.issued | 2010 | - |
dc.identifier.issn | 0030-2414 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/103141 | - |
dc.description.abstract | OBJECTIVE: The aims of this study were to identify prognostic factors for overall survival (OS) in patients with small cell lung cancer (SCLC) and to construct a prognostic index on the basis of their expected OS. Long-term survivors were also given special attention. METHODS: We retrospectively analyzed 295 patients diagnosed with SCLC from January 2002 to September 2007 at the Severance Hospital, Seoul, Republic of Korea. Patient history was reviewed regarding both clinical and tumor-related markers, and treatment-related factors were also evaluated. RESULTS: There were 131 (44.4%) patients with limited disease (LD) and 164 (55.6%) with extensive disease (ED). Median follow-up lasted 9.4 months. Objective response to chemotherapy was 66.8%. The median survival time (MST) was 11.2 months in all patients, 20.4 months in LD patients, and 7.7 months in ED patients. The median progression-free survival was 9.4 months. Independent prognostic factors for overall survival (OS) were extent of disease, performance status, and CYFRA 21-1 level. We classified all patients into four groups based on the results of multivariate analysis using classification and regression tree analysis. Median survival times were 22.7, 13.7, 8.5, and 3.2 months, respectively. A total of 51 (17.3%) patients from the entire study population were evaluated for long-term survival, which was defined as survival >2 years. Their MST was 43.1 months, and extent of disease, performance status, and CYFRA 21-1 were independent prognostic factors for long-term survival. CONCLUSIONS: We confirmed the well-known prognosticators, disease extent and performance status, in our patients, but further identified CYFRA 21-1 as independent prognostic factor. A prognostic index was constructed to create four classifications of SCLC considering these variables | - |
dc.description.statementOfResponsibility | open | - |
dc.format.extent | 293~300 | - |
dc.relation.isPartOf | ONCOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Aged, 80 and over | - |
dc.subject.MESH | Antigens, Neoplasm/metabolism | - |
dc.subject.MESH | Antineoplastic Combined Chemotherapy Protocols/therapeutic use* | - |
dc.subject.MESH | Bone Neoplasms/drug therapy | - |
dc.subject.MESH | Bone Neoplasms/mortality | - |
dc.subject.MESH | Bone Neoplasms/secondary | - |
dc.subject.MESH | Brain Neoplasms/drug therapy | - |
dc.subject.MESH | Brain Neoplasms/mortality | - |
dc.subject.MESH | Brain Neoplasms/secondary | - |
dc.subject.MESH | Carcinoma, Squamous Cell/drug therapy | - |
dc.subject.MESH | Carcinoma, Squamous Cell/mortality* | - |
dc.subject.MESH | Carcinoma, Squamous Cell/pathology | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Follow-Up Studies | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Keratin-19/metabolism | - |
dc.subject.MESH | Liver Neoplasms/drug therapy | - |
dc.subject.MESH | Liver Neoplasms/mortality | - |
dc.subject.MESH | Liver Neoplasms/secondary | - |
dc.subject.MESH | Lung Neoplasms/drug therapy | - |
dc.subject.MESH | Lung Neoplasms/mortality* | - |
dc.subject.MESH | Lung Neoplasms/pathology | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Neoplasm Staging | - |
dc.subject.MESH | Prognosis | - |
dc.subject.MESH | Republic of Korea | - |
dc.subject.MESH | Retrospective Studies | - |
dc.subject.MESH | Small Cell Lung Carcinoma/drug therapy | - |
dc.subject.MESH | Small Cell Lung Carcinoma/mortality* | - |
dc.subject.MESH | Small Cell Lung Carcinoma/pathology | - |
dc.subject.MESH | Survival Rate | - |
dc.subject.MESH | Survivors* | - |
dc.title | Prognostic factors in small cell lung cancer: a new prognostic index in Korean patients | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학) | - |
dc.contributor.googleauthor | Hong S. | - |
dc.contributor.googleauthor | Cho B.C. | - |
dc.contributor.googleauthor | Choi H.J. | - |
dc.contributor.googleauthor | Jung M. | - |
dc.contributor.googleauthor | Lee S.H. | - |
dc.contributor.googleauthor | Park K.S. | - |
dc.contributor.googleauthor | Kim S.K. | - |
dc.contributor.googleauthor | Kim J.H. | - |
dc.identifier.doi | 10.1159/000323333 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A00602 | - |
dc.contributor.localId | A00945 | - |
dc.contributor.localId | A01422 | - |
dc.contributor.localId | A03606 | - |
dc.contributor.localId | A03822 | - |
dc.contributor.localId | A04219 | - |
dc.contributor.localId | A04410 | - |
dc.contributor.localId | A02898 | - |
dc.relation.journalcode | J02416 | - |
dc.identifier.eissn | 1423-0232 | - |
dc.identifier.pmid | 21412014 | - |
dc.identifier.url | http://www.karger.com/Article/FullText/323333 | - |
dc.subject.keyword | CYFRA 21-1 | - |
dc.subject.keyword | Disease extent | - |
dc.subject.keyword | Performance status | - |
dc.subject.keyword | Prognostic factors | - |
dc.subject.keyword | Small cell lung cancer | - |
dc.subject.keyword | Survival | - |
dc.contributor.alternativeName | Kim, Se Kyu | - |
dc.contributor.alternativeName | Kim, Joo Hang | - |
dc.contributor.alternativeName | Park, Kyung Soo | - |
dc.contributor.alternativeName | Lee, Soo Hyeon | - |
dc.contributor.alternativeName | Jung, Min Kyu | - |
dc.contributor.alternativeName | Cho, Byoung Chul | - |
dc.contributor.alternativeName | Choi, Hye Jin | - |
dc.contributor.alternativeName | Hong, Soo Jung | - |
dc.contributor.affiliatedAuthor | Kim, Se Kyu | - |
dc.contributor.affiliatedAuthor | Kim, Joo Hang | - |
dc.contributor.affiliatedAuthor | Park, Kyung Soo | - |
dc.contributor.affiliatedAuthor | Jung, Min Kyu | - |
dc.contributor.affiliatedAuthor | Cho, Byoung Chul | - |
dc.contributor.affiliatedAuthor | Choi, Hye Jin | - |
dc.contributor.affiliatedAuthor | Hong, Soo Jung | - |
dc.contributor.affiliatedAuthor | Lee, Soo Hyeon | - |
dc.citation.volume | 79 | - |
dc.citation.number | 3-4 | - |
dc.citation.startPage | 293 | - |
dc.citation.endPage | 300 | - |
dc.identifier.bibliographicCitation | ONCOLOGY, Vol.79(3-4) : 293-300, 2010 | - |
dc.identifier.rimsid | 35719 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.